Kai Ding

Tianjin Key Laboratory Of Bone Marrow Failure And Malignant Hemopoietic Clone Control
Tianjin, 300052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

A metabolically reprogrammable nanoplatform potentiates photodynamic immunotherapy through glycolytic blockade.

A metabolically reprogrammable nanoplatform potentiates photodynamic immunotherapy through glycolytic blockade.

Journal: Biomaterials

Published: March 23, 2026

Microvesicles derived from bone marrow and peripheral blood can reflect tumor load in multiple myeloma.

Microvesicles derived from bone marrow and peripheral blood can reflect tumor load in multiple myeloma.

Journal: Journal of translational internal medicine

Published: February 23, 2026

Correction: Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

Correction: Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

Journal: Journal of translational medicine

Published: November 22, 2025

Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.

Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.

Journal: International journal of biological sciences

Published: November 04, 2025

Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.

Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: September 22, 2025

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.

Journal: British journal of haematology

Published: July 03, 2025

Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.

Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: May 23, 2025

T-lymphocytes suppression by CD14+ monocytes with high expression of ULK2 in patients with multiple myeloma.

T-lymphocytes suppression by CD14+ monocytes with high expression of ULK2 in patients with multiple myeloma.

Journal: Journal of translational medicine

Published: March 18, 2025

Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.

Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 09, 2025

Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition.

Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition.

Journal: BMC cancer

Published: January 18, 2025

Chimeric antigen receptor T cell therapy based on stem cell-like memory T cells enhances anti-tumour effects in multiple myeloma.

Chimeric antigen receptor T cell therapy based on stem cell-like memory T cells enhances anti-tumour effects in multiple myeloma.

Journal: Clinical and translational medicine

Published: January 17, 2025

Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

Journal: Journal of translational medicine

Published: January 16, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026